Skip to main content

Remote Job Finders (RJF)

With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys

After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squibb, which spent $14 billion for Karuna just two weeks later.
Scroll to top